- Stocks
- Healthcare
- NASDAQ: IART

Price (delayed)

$24.04

Market cap

$1.87B

P/E Ratio

80.13

Dividend/share

N/A

EPS

$0.3

Enterprise value

$3.66B

Integra LifeSciences is a global leader in regenerative tissue technologies and neurosurgical solutions dedicated to limiting uncertainty for clinicians, so they can focus on providing the best patient care. Integra

The revenue is up by 2.4% since the previous quarter

IART's quick ratio is down by 42% from the previous quarter but it is up by 15% YoY

The gross profit has declined by 5% year-on-year but it is up by 2.2% since the previous quarter

Integra Lifesciences Holdings's net income has plunged by 82% YoY and by 41% from the previous quarter

IART's EPS has dropped by 81% year-on-year and by 41% since the previous quarter

What are the main financial stats of IART

Market
Valuations
Earnings

Shares outstanding

77.58M

Market cap

$1.87B

Enterprise value

$3.66B

Price to earnings (P/E)

80.13

Price to book (P/B)

1.23

Price to sales (P/S)

1.19

EV/EBIT

42.48

EV/EBITDA

16.93

EV/Sales

2.34

Revenue

$1.57B

EBIT

$86.14M

EBITDA

$216.16M

Free cash flow

$58.89M

Per share
Balance sheet
Liquidity

EPS

$0.3

Free cash flow per share

$0.76

Book value per share

$19.47

Revenue per share

$20.24

TBVPS

$22.61

Total assets

$4.07B

Total liabilities

$2.54B

Debt

$2.01B

Equity

$1.53B

Working capital

$783.97M

Debt to equity

1.31

Current ratio

3.39

Quick ratio

1.73

Net debt/EBITDA

8.3

Margins
Efficiency
Dividend

EBITDA margin

13.8%

Gross margin

56%

Net margin

1.5%

Operating margin

4.1%

Return on assets

0.6%

Return on equity

1.5%

Return on invested capital

2.9%

Return on capital employed

2.3%

Return on sales

5.5%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Integra Lifesciences Holdings stock price performed over time

Intraday

-2.32%

1 week

-23.51%

1 month

-17.64%

1 year

-45.95%

YTD

-44.8%

QTD

-17.5%

How have Integra Lifesciences Holdings's revenue and profit performed over time

Revenue

$1.57B

Gross profit

$877.59M

Operating income

$63.58M

Net income

$23.65M

Gross margin

56%

Net margin

1.5%

Integra Lifesciences Holdings's net income has plunged by 82% YoY and by 41% from the previous quarter

The net margin has dropped by 82% year-on-year and by 42% since the previous quarter

The operating income has dropped by 65% year-on-year and by 20% since the previous quarter

IART's operating margin has dropped by 65% year-on-year and by 21% since the previous quarter

What is Integra Lifesciences Holdings's growth rate over time

What is Integra Lifesciences Holdings stock price valuation

P/E

80.13

P/B

1.23

P/S

1.19

EV/EBIT

42.48

EV/EBITDA

16.93

EV/Sales

2.34

IART's EPS has dropped by 81% year-on-year and by 41% since the previous quarter

The stock's price to earnings (P/E) is 61% more than its 5-year quarterly average of 51.0 and 32% more than its last 4 quarters average of 62.2

The P/B is 55% lower than the 5-year quarterly average of 2.8 and 30% lower than the last 4 quarters average of 1.8

The equity has declined by 9% year-on-year and by 4% since the previous quarter

The price to sales (P/S) is 58% less than the 5-year quarterly average of 2.9 and 36% less than the last 4 quarters average of 1.9

The revenue is up by 2.4% since the previous quarter

How efficient is Integra Lifesciences Holdings business performance

IART's ROA has shrunk by 83% YoY and by 40% QoQ

Integra Lifesciences Holdings's return on equity has shrunk by 80% YoY and by 40% QoQ

IART's return on invested capital has dropped by 64% year-on-year and by 17% since the previous quarter

IART's return on sales has dropped by 59% year-on-year and by 15% since the previous quarter

What is IART's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for IART.

How did Integra Lifesciences Holdings financials performed over time

The company's total assets is 60% higher than its total liabilities

IART's quick ratio is down by 42% from the previous quarter but it is up by 15% YoY

The current ratio has declined by 28% since the previous quarter but it has grown by 22% year-on-year

The debt is 31% greater than the equity

Integra Lifesciences Holdings's debt to equity has increased by 38% YoY and by 2.3% QoQ

The debt is up by 25% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.